Adult Vaccines Market: Global Industry Insights Analysis and Forecast to 2025

Vaccination is one of the most effective and safest therapies that provides protection against diseases. Most vaccines are recommended on the basis of age, lifestyle, travel destinations, and health conditions such as diabetes, heart diseases, asthma, and chronic obstructive pulmonary disease (COPD). According to Centers for Disease Control and Prevention (CDC), in 2013, around 226,000 people are hospitalized every year and between 3,000 and 49,000 people die due to influenza and its complications, with major being adults. CDC recorded the financial burden of adult vaccine preventable diseases (VPD) in the U.S. to be around US$ 10 billion, annually and recommends adults to be vaccinated against various infections such as influenza, pertussis (whooping cough), chickenpox, diphtheria, measles, hepatitis A and B, meningococcal disease (meningitis), human papillomavirus, mumps, pneumococcal disease (pneumonia), rubella, shingles, and tetanus.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1091

Initiatives by state authorities against viral and bacterial infections and innovation of novel vaccines is expected to fuel growth of the market

In August 2017, GlaxoSmithKline and Ali health promoted HPV/Cervarix – which is a part of online shopping program named Taobao. It offers several pediatric and adult vaccine information and links of 1500 health clinics for consultations and appointments in China. This in turn, is expected to fuel growth of the adult vaccines market in the near future. Moreover, Dallas County Health and Human Services (DCHHS), in August 2017, offered seasonal flu vaccine for adults, which is an all-in-one shot vaccine for multiple flu strains, including H1N1.

According to Public Health England (PHE), reported that nasal influenza vaccine reduced risk of influenza for children, however, not for adults. PHS suggest the development of new vaccines, which may provide better protection from infections among the geriatric population. This in turn, is expected to provide key players operating in adult vaccine market, high opportunity to develop effective vaccines for geriatric population.

Increasing prevalence infections among adults fuels growth of the adult vaccines market

According to the Immunization Action Coalition (IAC), a member of the WHO-led project Vaccine Safety Net (VSN), around 166,000 cases of flu were reported in the U.S. and around 71 people died in September 2017. Moreover, in 2016, around 91,000 people were impacted from flu over the last five years. Moreover, in Canada, Vancouver Coastal Health issued a warning to teens and young adults against mumps in 2017. According to CDC, people traveling every year for business and vacations are at a higher risk of developing infections. The state and local healthcare authorities have made vaccination a compulsion for travelers, which in turn, is expected to fuel growth of the adult vaccines market.

Key players operating in the global adult vaccines market include GlaxoSmithKline plc, Panacea Biotec, Pfizer, Inc., Protein Sciences Corporation, Merck & Co., Inc., Daiichi Sankyo, Sanofi Pasteur SA, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Bavarian Nordic, CSL Limited, Serum Institute of India Pvt. Ltd., ), Emergent BioSolutions, Inc., MedImmune, LLC, and Johnson & Johnson.

Browse Market Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/adult-vaccines-market-1091

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com

This release was published on openPR.